Natera (NASDAQ:NTRA) CEO Sells $881,499.84 in Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 3,848 shares of Natera stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $229.08, for a total value of $881,499.84. Following the completion of the sale, the chief executive officer directly owned 136,568 shares of the company’s stock, valued at $31,284,997.44. This trade represents a 2.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Steven Leonard Chapman also recently made the following trade(s):

• On Monday, December 1st, Steven Leonard Chapman sold 4,400 shares of Natera stock. The stock was sold at an average price of $238.07, for a total value of $1,047,508.00.
• On Monday, November 3rd, Steven Leonard Chapman sold 160,703 shares of Natera stock. The shares were sold at an average price of $199.96, for a total transaction of $32,134,171.88.
• On Tuesday, October 28th, Steven Leonard Chapman sold 3,680 shares of Natera stock. The shares were sold at an average price of $191.46, for a total transaction of $704,572.80.
• On Monday, October 27th, Steven Leonard Chapman sold 2,335 shares of Natera stock. The stock was sold at an average price of $192.32, for a total transaction of $449,067.20.
• On Tuesday, October 21st, Steven Leonard Chapman sold 1,603 shares of Natera stock. The stock was sold at an average price of $187.95, for a total value of $301,283.85.

Natera Stock Performance

Shares of NTRA stock opened at $239.56 on Friday. The company has a market capitalization of $33.14 billion, a price-to-earnings ratio of -104.61 and a beta of 1.62. The company has a 50-day simple moving average of $226.34 and a 200 day simple moving average of $185.64. Natera, Inc. has a 52 week low of $125.38 and a 52 week high of $256.36.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). The business had revenue of $592.18 million during the quarter, compared to analyst estimates of $514.55 million. Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The firm’s quarterly revenue was up 34.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.26) earnings per share. Sell-side analysts forecast that Natera, Inc. will post -1.49 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Horizon Investments LLC purchased a new position in Natera during the third quarter worth $32,000. Northwestern Mutual Wealth Management Co. boosted its position in Natera by 83.5% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company’s stock valued at $33,000 after buying an additional 106 shares during the last quarter. Hilltop National Bank purchased a new position in shares of Natera during the 2nd quarter valued at approximately $33,000. Oliver Lagore Vanvalin Investment Group purchased a new stake in shares of Natera during the second quarter worth about $36,000. Finally, Sound Income Strategies LLC lifted its stake in Natera by 95.7% in the 3rd quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock worth $39,000 after purchasing an additional 110 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors.

Key Stories Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Major banks initiate or reaffirm buy ratings on Natera, which can attract more institutional demand and support the stock. Citigroup initiates coverage of Natera (NTRA) with buy recommendation
• Positive Sentiment: Piper Sandler issued a buy on Natera, reinforcing recent bullish analyst activity and signaling continued confidence in the company’s growth trajectory. Natera (NTRA) Receives a Buy from Piper Sandler
• Positive Sentiment: Guggenheim reiterated its buy rating, joining other firms that have raised price targets — a supportive backdrop for sentiment and mid‑term upside. Guggenheim Sticks to Their Buy Rating for Natera (NTRA)
• Positive Sentiment: Natera announced a collaboration with Exelixis on the phase 3 STELLAR‑316 colorectal cancer trial — this expands potential clinical use cases for Natera’s oncology assays and could drive future revenue if tied to companion diagnostics/monitoring. Exelixis and Natera to Collaborate on STELLAR-316
• Neutral Sentiment: Analyst consensus remains skewed positive overall (MarketBeat/AmericanBankingNews show a “Moderate Buy” average rating and a consensus price target in the low‑to mid‑$200s), implying expectations are baked into current levels. Natera, Inc. (NASDAQ:NTRA) Receives Average Recommendation of “Moderate Buy” from Analysts
• Neutral Sentiment: Routine market data/price pages track the share move but add no new catalyst. Natera (NTRA) share price
• Negative Sentiment: Significant insider selling was reported (aggregate reports note roughly US$47M in insider sales recently), which can signal near‑term liquidity or confidence concerns and often pressures the stock. Insiders At Natera Sold US$47m In Stock
• Negative Sentiment: Company insiders including CEO Steven Chapman and other executives (Solomon Moshkevich) recently filed Form 4 sales (small single‑digit percentage reductions in holdings). Multiple, recurring insider sales can amplify investor caution. Solomon Moshkevich Sells 2,951 Shares of Natera (NASDAQ:NTRA) Stock

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Canaccord Genuity Group upped their target price on shares of Natera from $250.00 to $285.00 and gave the stock a “buy” rating in a research note on Monday, December 22nd. Zacks Research upgraded shares of Natera from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. Morgan Stanley lifted their target price on shares of Natera from $220.00 to $265.00 and gave the stock an “overweight” rating in a research note on Monday, December 1st. Evercore ISI lifted their price objective on Natera from $190.00 to $250.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. Finally, BTIG Research boosted their target price on Natera from $230.00 to $260.00 and gave the stock a “buy” rating in a report on Friday, December 5th. Sixteen research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $238.89.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.